Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- Talion Authorized Generics Rack Up 1.5 Billion Yen in Single Month
May 18, 2018
- Fujifilm’s Cancer Peptide Vaccine Flops in Japan PIII
May 18, 2018
- Sawai Seeks Strategical Alliance, Intra-Industry Network under New Midterm Biz Plan
May 18, 2018
- 10 Major Japan Drug Makers’ Sales Up 3.3%, but Decline Expected for FY2018 on Price Revision
May 18, 2018
- Alecensa Approved for 1st-Line Treatment of NSCLC in Taiwan: Chugai
May 17, 2018
- Daiichi Sankyo, Canadian Biotech Expand Joint Research on Bispecific Antibodies
May 16, 2018
- Gilead Seeks Japan Approval for Epclusa
May 16, 2018
- Towa Aims at Expansion into US and ASEAN Markets, Annual Sales of 100 Billion Yen under New 3-Year Plan
May 16, 2018
- Nichi-Iko, Eisai to Copromote Partner’s Generics from October
May 16, 2018
- Eisai Poised to Focus on Maximization of Lenvima Value: CEO
May 16, 2018
- Eisai Chalks Up 1st Double-Digit Growth in 11 Years on Merck Deal, Global Brands
May 16, 2018
- Taisho to Launch Voluntary Redundancy Program
May 15, 2018
- Velcade Sales Would Slide 50%, but Weber Stresses Takeda’s Strong Momentum
May 15, 2018
- Taisho and Fujifilm to Dissolve Capital Alliance and Transform Their JV Companies to Wholly Owned Subsidiaries
May 15, 2018
- Takeda Delivers Double-Digit Profit Growth as Entyvio Nets 200-Plus Billion Yen
May 15, 2018
- Lilly, Sapporo Medical Univ. Ink Antigen Research Deal for Colorectal Cancer Immunotherapy
May 14, 2018
- Santen Plans Add’l Trial on Uveitis Treatment DE-109 after FDA Rebuff
May 14, 2018
- Latuda Use Patent Suit Could Wrap Up in December: Sumitomo Dainippon Chief
May 14, 2018
- Towa Wins Top Court Victory over Elplat Patent
May 14, 2018
- Kyorin Holdings Aims to Boost New Drug Sales to Over 50% of Overall Sales by FY2019: Pres.
May 14, 2018
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…